A global phase 1b study of ORIC-114, a highly selective, brain penetrant EGFR and HER2 inhibitor, in patients with advanced solid tumors harboring EGFR Exon 20 or HER2 alterations

被引：5
|
作者：
Hong, M. H. [1 ]
Spira, A. I. [2 ]
Lee, K. H. [3 ]
Cho, E. K. [4 ]
Han, J-Y. [5 ]
Shim, B. Y. [6 ]
Lee, J-S. [7 ]
Kao, S. C-H. [8 ]
Kim, S-W. [9 ]
Khattak, A. [10 ]
Patel, M. [11 ]
Xu, R. [11 ]
Wang, J. [11 ]
Ariazi, E. [12 ]
Daemen, A. [12 ]
Maneval, E. Chow [11 ]
Multani, P. S. [11 ]
Patel, R. [11 ]
Ahn, M-J. [13 ]
机构：
[1] Yonsei Univ, Severance Hosp, Dept Internal Med, Coll Med, Seoul, South Korea
[2] Virginia Canc Specialist & Next Oncol, Res Inst, Fairfax, VA USA
[3] Chungbuk Natl Univ Hosp, Dept Internal Med, Cheongju, South Korea
[4] Gachon Univ, Dept Internal Med, Gil Hosp, Incheon, South Korea
[5] Natl Canc Ctr, Ctr Lung Canc, Grad Sch Canc Sci & Policy, Goyang, South Korea
[6] Catholic Univ Korea, Dept Med Oncol, St Vincents Hosp, Suwon, South Korea
[7] Seoul Natl Univ, Dept Internal Med, Bundang Hosp, Seongnam, Gyeonggi Do, South Korea
[8] Chris OBrien Lifehouse, Med Oncol Dept, Camperdown, NSW, Australia
[9] Univ Ulsan, Dept Oncol, Asan Med Ctr, Seoul, South Korea
[10] Hollywood Med Ctr, One Clin Res, Med Oncol, Nedlands, WA, Australia
[11] ORIC Pharmaceut Inc, Clin Dev, San Diego, CA USA
[12] ORIC Pharmaceut Inc, Translat Med, San Diego, CA USA
[13] Sungkyunkwan Univ, Dept Hematol Oncol, Samsung Med Ctr SMC, Sch Med, Seoul, South Korea
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2366
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1333P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] ORIC-114, a highly selective, brain penetrant EGFR and HER2 inhibitor, demonstrates best-in-class properties against Exon 20 insertions and other atypical EGFR mutations
    Junttila, M.
    Repellin, C. E.
    Warne, R.
    Long, J. E.
    Sambucetti, L.
    Ashley, P.
    Andreatta, G.
    Baik, J.
    Salaniwal, S.
    Colas, C.
    Romero, A.
    Soroceanu, L.
    Patel, R.
    Maneval, E. Chow
    Multani, P. S.
    Daemen, A.
    Friedman, L.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S28 - S28
  • [2] ORIC-114, a brain penetrant, orally bioavailable, irreversible inhibitor selectively targets EGFR and HER2 exon20 insertion mutants and regresses intracranial NSCLC xenograft tumors.
    Junttila, Melissa R.
    Kim, Sunghwan
    Lee, Younho
    Kim, Hwan
    Kang, Juhee
    Seok, Jiyoon
    Yoo, Jihye
    Lee, Youngyi
    Seo, Dong-Hyuk
    Son, Jung Beom
    Kim, Daekwon
    Choi, Hwan Geun
    Kim, Nam Doo
    Das, Akash
    Sutimantanapi, Dena
    Zavorotinskaya, Tatiana
    Chen, Chelsea
    Chang, Jae
    Panuwat, Matthew
    Friedman, Lori
    CANCER RESEARCH, 2021, 81 (13)
  • [3] A Phase I Trial of the HER2 Exon 20 Inhibitor, BI 1810631, In Patients With Advanced Solid Tumors With HER2 Aberrations
    Opdam, F.
    Heymach, J.
    Barve, M.
    Gibson, N.
    Sadrolhefazi, B.
    Serra, J.
    Yamamoto, N.
    Yoh, K.
    Wu, Y. -L.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S421 - S422
  • [4] A Phase 1b Study Of Furmonertinib, an Oral, Brain Penetrant, Selective EGFR Inhibitor, in Patients with Advanced NSCLC with EGFR Exon 20 Insertions
    Han, B.
    Zhou, C.
    Zheng, W.
    Wu, L.
    Ma, Z.
    Wang, H.
    Yu, X.
    Ding, G.
    Ma, D.
    Nie, L.
    Zhang, Z.
    Dong, X.
    Shang, Y.
    Tang, K.
    Zhang, W.
    Hsu, J. Y.
    Jiang, Y.
    Zhao, Q.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S49 - S49
  • [5] IAM1363-01: A phase 1/1b study of a selective and brain-penetrant HER2 inhibitor for HER2-driven solid tumors.
    Adjei, Alex A.
    Wong, Kwok-Kin
    Koehler, Maria
    Spira, Alexander I.
    Jameson, Katherine L.
    Chapman, Deb
    Walling, Jacqueline M.
    Josephson, Neil C.
    Huang, Zhongdong
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] Phase 1 Studies of DZD9008, an Oral Selective EGFR/HER2 Inhibitor in Advanced NSCLC with EGFR Exon20 Insertion Mutations
    Janne, P.
    Wang, M.
    Mitchell, P.
    Fang, J.
    Nian, W.
    Chiu, C.
    Zhou, J.
    Zhao, Y.
    Su, W.
    Camidge, D. R.
    Yang, T.
    Zhu, V.
    Millward, M.
    Fan, Y.
    Huang, W.
    Cheng, Y.
    Jiang, L.
    Brungs, D.
    Bazhenova, L.
    Lee, C. K.
    Gao, B.
    Qi, S.
    Yu, X.
    Deng, C.
    Chen, K.
    Ye, X.
    Zheng, L.
    Yang, Z.
    Yang, J. C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S874 - S874
  • [7] Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors
    Yap, Timothy A.
    Vidal, Laura
    Adam, Jan
    Stephens, Peter
    Spicer, James
    Shaw, Heather
    Ang, Jooern
    Temple, Graham
    Bell, Susan
    Shahidi, Mehdi
    Uttenreuther-Fischer, Martina
    Stopfer, Peter
    Futreal, Andrew
    Calvert, Hilary
    de Bono, Johann S.
    Plummer, Ruth
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (25) : 3965 - 3972
  • [8] Preclinical evaluation of DS-2087b, a novel and selective inhibitor of EGFR/HER2 exon 20 insertions
    Nagamoto, Y.
    Miyamoto, M.
    Togashi, N.
    Taira, T.
    Jimbo, T.
    Isoyama, T.
    Takahashi, M.
    Takeuchi, K.
    Yoshida, K-I.
    Higuchi, S.
    Seki, T.
    Abe, Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S248 - S248
  • [9] A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors
    Jian Zhang
    Junning Cao
    Jin Li
    Yifan Zhang
    Zhiyu Chen
    Wei Peng
    Si Sun
    Naiqing Zhao
    Jiachen Wang
    Dafang Zhong
    Xiaofang Zhang
    Jing Zhang
    Journal of Hematology & Oncology, 7
  • [10] A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors
    Zhang, Jian
    Cao, Junning
    Li, Jin
    Zhang, Yifan
    Chen, Zhiyu
    Peng, Wei
    Sun, Si
    Zhao, Naiqing
    Wang, Jiachen
    Zhong, Dafang
    Zhang, Xiaofang
    Zhang, Jing
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2014, 7
12345